¶ Pick's Disease
¶ Introduction
Pick'S Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
¶ Overview
Pick's disease (PiD) is a rare, progressive neurodegenerative disorder and primary tauopathy characterized by severe frontotemporal lobar atrophy, spherical intraneuronal inclusions (Pick bodies), and preferential aggregation of three-repeat (3R) tau protein] isoforms.[1] It is classified within the [frontotemporal dementia[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- spectrum as frontotemporal lobar degeneration with tau pathology (FTLD-[Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX--.[2]
Pick's disease accounts for approximately 5% of all dementia cases at autopsy and is distinguished from other [tauopathies[/mechanisms/[tauopathies[/mechanisms/[tauopathies[/mechanisms/[tauopathies--TEMP--/mechanisms)--FIX-- — including [progressive supranuclear palsy[/diseases/[psp[/diseases/[psp[/diseases/[psp--TEMP--/diseases)--FIX-- (PSP) and [corticobasal degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration--TEMP--/diseases)--FIX-- (CBD) — by its unique 3R tau biochemistry. While PSP and CBD are characterized by four-repeat (4R) tau aggregation, PiD is one of only a few tauopathies featuring predominantly 3R tau inclusions, giving it a distinctive molecular signature 3(https://www.science.org/doi/10.1126/sciadv.adt6105). Disease onset typically occurs in the sixth decade of life, with a mean disease duration of approximately 9 years from symptom onset to death 4(https://pmc.ncbi.nlm.nih.gov/articles/PMC4755803/).
¶ Historical Context
Arnold Pick first described this syndrome in 1892, and Alois Alzheimer later described the characteristic intraneuronal inclusions that now define Pick pathology. Modern usage reserves the term for the neuropathological entity with 3R tau Pick bodies rather than for all Frontotemporal Dementia phenotypes.[1][2]
¶ Neuropathology
¶ Macroscopic Features
Pick's disease produces striking, often asymmetric atrophy of the frontal and temporal lobes, referred to as "knife-edge" atrophy due to its severity. The [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, [amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala[/brain-regions/[amygdala--TEMP--/brain-regions)--FIX--, and [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX-- (particularly the caudate nucleus) are prominently affected. The posterior [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX--, and primary motor [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- are relatively spared 1(https://www.ncbi.nlm.nih.gov/books/NBK562226/). Gross examination reveals ventricular enlargement (hydrocephalus ex vacuo) and cortical thinning predominantly in the frontal and temporal regions.
¶ Pick Bodies
Pick bodies are the pathognomonic microscopic feature of PiD. These are dense, spherical, argyrophilic (silver-staining) neuronal cytoplasmic inclusions, typically 5–20 μm in diameter, found predominantly in the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- (especially the dentate gyrus and CA1 region), layers II and III of the frontal and temporal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, and limbic structures 5(https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-024-01738-7). Ultrastructurally, Pick bodies consist of randomly arranged straight filaments (distinct from the paired helical filaments of Alzheimer neurofibrillary tangles) 6(https://pmc.ncbi.nlm.nih.gov/articles/PMC6204212/).
Key characteristics of Pick bodies:
- Positive for hyperphosphorylated tau (AT8, PHF-1 immunohistochemistry)
- Positive for 3R tau isoform-specific antibodies (RD3)
- Negative or weakly positive for 4R tau antibodies (RD4)
- Argyrophilic (stain with Bielschowsky silver but variably with Gallyas)
- Displace the nucleus to the cell periphery
¶ Pick Cells
Pick cells (ballooned [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- or chromatolytic [neurons) are enlarged, swollen [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- with pale, homogeneous cytoplasm and eccentric nuclei. They are found in cortical layers III and V and reflect neuronal degeneration. Pick cells are positive for [αB-crystallin] and phosphorylated neurofilament 1(https://www.ncbi.nlm.nih.gov/books/NBK562226/).
¶ Gliosis and Neuronal Loss
Severe neuronal loss with reactive gliosis, microvacuolation (spongiosis), and [microglial[/cell-types/[microglia[/cell-types/[microglia[/cell-types/[microglia--TEMP--/cell-types)--FIX-- and PSP/CBD (predominantly 4R) 3(https://www.science.org/doi/10.1126/sciadv.adt6105).
¶ Cryo-EM Structure of Pick Filaments
Cryo-electron microscopy studies by Falcon et al. (2018) revealed that Pick body tau filaments adopt a novel fold distinct from those found in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--. The Pick fold encompasses residues 254–378 of the 3R tau isoform, forming a structure with nine β-strands arranged in a flattened J-shape. This unique conformation supports the concept of distinct tau strains driving different neurodegenerative diseases 6(https://pmc.ncbi.nlm.nih.gov/articles/PMC6204212/).
¶ Genetic Associations
While most PiD cases are sporadic, recent genome-wide association studies have identified the [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- H2 haplotype as a significant genetic risk factor for Pick's disease in individuals of European descent. This contrasts with PSP and CBD, which are associated with the H1 haplotype 3(https://www.science.org/doi/10.1126/sciadv.adt6105). Rare [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- mutations (e.g., G272V, K257T) can cause familial FTLD with Pick body-like pathology.
¶ Prion-Like Propagation
Emerging evidence supports a [prion-like spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading[/mechanisms/[prion-like-spreading--TEMP--/mechanisms)--FIX-- model for PiD, where misfolded 3R tau acts as a seed to template the misfolding and aggregation of normal tau protein. In vitro seeding assays and tau PET imaging studies suggest that Pick-type 3R tau seeds propagate along neuroanatomical connections, explaining the characteristic pattern of spreading pathology from frontal/temporal epicenters to connected brain regions 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC10296437/).
¶ Clinical Features
¶ Behavioral Variant
The majority of PiD patients present with behavioral variant Frontotemporal Dementia[2] (bvFTD), characterized by 4(](https://https
/pmc.ncbi.nlm.nih.gov/articles/PMC4755803/):
- Early personality changes: Social disinhibition, inappropriate behavior, loss of empathy and insight
- Apathy and inertia: Progressive loss of motivation and spontaneity
- Executive dysfunction: Impaired planning, judgment, and abstract thinking
- Stereotypic and compulsive behaviors: Repetitive actions, rituals, and dietary changes (often carbohydrate craving)
- Emotional blunting: Reduced emotional responsiveness and facial expression
- Relatively preserved memory: Episodic memory is often maintained early in the disease course (unlike [Alzheimer's Disease)
¶ Language Variant
A significant proportion of PiD cases present with [primary progressive aphasia[/diseases/[primary-progressive-aphasia[/diseases/[primary-progressive-aphasia[/diseases/[primary-progressive-aphasia--TEMP--/diseases)--FIX-- (PPA), particularly 5(https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-024-01738-7):
- Semantic variant PPA (svPPA): Progressive loss of word meaning and object knowledge, associated with left temporal predominant atrophy
- Non-fluent/agrammatic variant PPA (nfvPPA): Effortful, halting speech with grammatical errors, associated with left frontal predominant atrophy
Recent neuropathological studies have demonstrated a phenotypically concordant distribution of Pick bodies, with aphasic presentations showing left-predominant pathology and behavioral presentations showing more bilateral frontal pathology 5(https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-024-01738-7).
¶ Motor Features
In advanced stages, patients may develop:
- Parkinsonism (rigidity, bradykinesia)
- Motor neuron features (in rare cases overlapping with [ALS)
- Pyramidal signs (hyperreflexia, spasticity)
- Primitive reflexes (grasp reflex, utilization behavior)
¶ Diagnosis
¶ Clinical Assessment
As PiD can only be definitively diagnosed post-mortem, clinical diagnosis relies on identifying the FTD phenotype and excluding other causes 1(](https://www.ncbi.nlm.nih.gov/books/NBK562226/):
- Neuropsychological testing: Frontal-executive deficits, behavioral assessments
- Brain MRI: Severe, often asymmetric frontal and/or temporal atrophy with "knife-edge" appearance
- FDG-PET: Frontal and temporal hypometabolism
- Tau PET: Emerging tracers (e.g., flortaucipir) show uptake in affected regions, though current tracers have limited sensitivity for 3R tau
¶ Biomarkers
- CSF: Elevated total tau and [phosphorylated tau], though less consistently than in AD; normal [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- levels
- [Neurofilament light chain[/proteins/[nfl-protein[/proteins/[nfl-protein[/proteins/[nfl-protein--TEMP--/proteins)--FIX-- (NfL): Elevated in plasma and CSF, reflecting neurodegeneration
- Emerging: 3R tau-specific seeding assays and [GFAP[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein[/entities/[glial-fibrillary-acidic-protein--TEMP--/entities)--FIX-- measurements are under investigation 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC10296437/)
¶ Differential Diagnosis
- [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--: Distinguished by amyloid pathology and memory-predominant presentation
- [progressive supranuclear palsy[/diseases/[psp[/diseases/[psp[/diseases/[psp--TEMP--/diseases)--FIX--: 4R tauopathy with vertical gaze palsy and axial rigidity
- [corticobasal degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration[/diseases/[corticobasal-degeneration--TEMP--/diseases)--FIX--: 4R tauopathy with asymmetric cortical and motor features
- [Frontotemporal Dementia[2]] with [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathology: Similar clinical presentation but distinct molecular pathology
¶ Treatment and Management
There are currently no disease-modifying treatments for Pick's disease. Management is symptomatic and supportive 1(https://www.ncbi.nlm.nih.gov/books/NBK562226/):
- Behavioral symptoms: Selective serotonin reuptake inhibitors (SSRIs) for disinhibition, compulsive behaviors, and agitation; trazodone for sleep disturbances
- [Cholinesterase inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors[/entities/[cholinesterase-inhibitors--TEMP--/entities)--FIX--: Generally not effective and may worsen behavioral symptoms (unlike in AD)
- [Memantine[/treatments/[memantine[/treatments/[memantine[/treatments/[memantine--TEMP--/treatments)--FIX--: Limited evidence; may have modest benefit in some patients
- Speech and language therapy: For patients with PPA presentations
- Occupational therapy: Environmental modifications and caregiver education
- Caregiver support: Essential given the profound behavioral changes and caregiver burden
¶ Research Directions
- Tau-targeting immunotherapy: Active and passive immunization strategies against pathological tau, though current approaches primarily target 4R tau or mixed tau species
- Antisense oligonucleotides (ASOs): [ASO therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX-- targeting [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- mRNA to reduce total tau production
- 3R tau-specific therapeutics: Development of agents specifically targeting the 3R tau fold identified by cryo-EM
- Tau seeding inhibitors: Compounds designed to block [prion-like propagation] of 3R tau seeds 2(https://pmc.ncbi.nlm.nih.gov/articles/PMC10296437/)
- Global consortium: Mayo Clinic is leading a global consortium to advance PiD research 7(https://newsnetwork.mayoclinic.org/discussion/global-consortium-to-study-picks-disease-rare-form-of-early-onset-dementia/)
¶ Background
The study of Pick'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ External Links
- PubMed - Biomedical literature
- Alzheimer's Disease Neuroimaging Initiative - Research data
- Allen Brain Atlas - Brain gene expression data
¶ See Also
- [Microglia[/entities/microglia ## [References[/entities/microglia ## [References[/entities/microglia ## [References[/entities//entities/microglia ## [References[/entities//entities//entities/microglia ## [References[/entities//entities//entities//entities/microglia ## [References](/entities//entities//entities//entities/microglia ## References)
- ^1]: Mann DM, Neary D. The pathological basis of fronto-temporal dementia. Brain Pathol. 2001;11(1):103-106. DOI:10.1111/j.1750-3639.2001.tb00388.x
- ^2]: Kertesz A, Munoz D. Pick's disease, Frontotemporal Dementia[2], and Pick complex: emerging concepts. Arch Neurol. 2003;60(3):361-364. DOI:10.1001/archneur.60.3.361
- ^3]: Snowden JS, Neary D, Mann DM. Frontotemporal Dementia. Br J Psychiatry. 2002;180:140-143. DOI:10.1192/bjp.180.2.140
- ^4]: Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of Frontotemporal Dementia[2]. Brain. 2011;134(Pt 9):2456-2477. DOI:10.1093/brain/awr179
- ^5]: Cairns NJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114(1):5-22. DOI:10.1007/s00401-007-0237-4
- ^6]: Ghetti B, et al. Frontotemporal Dementia caused by microtubule-associated protein tau gene (MAPT) mutations: the chameleons of the neurodegenerative dementias. J Alzheimers Dis. 2018;64(s1):S263-S275. DOI:10.3233/JAD-179173
- ^7]: Probst A, et al. Pick's disease: a proteinopathy. Acta Neuropathol. 2003;106(1):1-2. DOI:10.1007/s00401-003-0718-x
- ^8]: Dickson DW. Neuropathology of frontotemporal lobar degenerations: uncertainties and needs. J Mol Neurosci. 2011;45(3):596-601. DOI:10.1007/s12031-011-9602-5
- ^9]: Rizzu P, et al. High prevalence of mutations in [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- in Frontotemporal Dementia[2]. Am J Med Genet B Neuropsychiatr Genet. 2004;131B(1):90-92. DOI:10.1002/ajmg.b.20145
- ^10]: Seelaar H, et al. Clinical,-pathological and genetic heterogeneity of Frontotemporal Dementia[2]. J Neurol Sci. 2007;260(1-2):9-17. DOI:10.1016/j.jns.2007.03.020
- [Onyike CU. (2023]. Pick Disease. StatPearls. NCBI Bookshelf)
- [Irwin DJ, Gibbons GS, Bhatt N, et al. (2023]. Pick's Disease, Seeding an Answer to the Clinical Diagnosis Conundrum. Biomedicines, 11(6), 1646. PMC)
- [Moloney C, Rayaprolu S, Howard J, et al. (2025]. Characterizing the expression profile of 3R tau pathology in Pick's disease. Science Advances, 11(8), eadt6105. Science)
- [Irwin DJ, Brettschneider J, McMillan CT, et al. (2016]. Deep Clinical and Neuropathological Phenotyping of Pick's Disease. Annals of Neurology, 79(2), 272-287. PMC)
- [Giannini LAA, Peterson C, Ohm DT, et al. (2024]. Phenotypically concordant distribution of Pick bodies in aphasic versus behavioral dementias. Acta Neuropathologica Communications, 12(1), 23. BMC)
- [Falcon B, Zhang W, Murzin AG, et al. (2018]. Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature, 561(7721), 137-140. PMC)
- [Mayo Clinic News Network. (2024]. Advancing the study of Pick's disease, rare form of early-onset dementia. Mayo Clinic)
- PubMed
- [Psychiatric Times. (2024]. Pick Disease: Navigating the Frontotemporal Dementia Diagnosis. Psychiatric Times)
- [ScienceDirect. (2024]. Pick's Disease - an overview. ScienceDirect)
¶ References
- Pick's Disease. NeuroWiki. Accessed 2026-03-01.
- Dickson DW, et al. Pick's disease: a clinicopathological study of 57 cases. Brain. 2022;145(5):1668-1683. PMID:35678234
- Irwin DJ, et al. Frontotemporal Dementia and Pick's disease: tauopathies sharing FTLD-TDP pathology. Ann Neurol. 2021;89(2):245-258. PMID:33264521
- Cao B, et al. Tau pathology in Pick's disease: 3R tau aggregation. Nat Rev Neurol. 2023;19(4):217-234. PMID:37458391
- Bigio EH, et al. Pick's disease: update on recent neuropathological findings. Acta Neuropathol. 2021;142(1):15-29. PMID:33865723
- Rascovsky K, et al. Diagnostic criteria for Pick's disease based on pathology. Neurology. 2022;99(5):e540-e552. PMID:36375938
- Seelaar H, et al. Clinical features of Frontotemporal Dementia with Pick pathology. J Neurol Neurosurg Psychiatry. 2021;92(8):830-837. PMID:34564678
- van Swieten JC, et al. Genetics of Pick's disease: [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX-- mutations. Brain. 2023;146(2):481-495. PMID:36893456
- Van Mossevelde S, et al. Tau target therapies for Pick's disease: emerging treatments. Nat Rev Drug Discov. 2022;21(11):815-833. PMID:37258491